Summary
Boston Scientific Corporation (BSX) reported a net income of $25 million ($0.06 per diluted share) for the second quarter of 2002, a significant improvement from a net loss of $172 million ($0.43 per diluted share) in the same period of the prior year. For the first six months of 2002, net income was $107 million ($0.26 per diluted share), compared to a net loss of $177 million ($0.44 per diluted share) for the same period in 2001. Net sales increased by 5% to $708 million for the second quarter and by 4% to $1,383 million for the first six months, driven by growth in product lines outside of coronary stents and contributions from recent acquisitions, despite a continued decline in NIR(R) coronary stent sales. The company completed two strategic acquisitions in the second quarter: Enteric Medical Technologies, Inc. (EMT) for GERD treatment technology and BEI Medical Systems Company, Inc. for women's health solutions, reflecting a strategy of combining internal development with external acquisitions. The company also substantially completed its global operations plan aimed at optimizing manufacturing and R&D facilities, expecting significant cost savings.
Key Highlights
- 1Positive shift to profitability: Reported net income of $25 million in Q2 2002, a substantial turnaround from a net loss of $172 million in Q2 2001. Year-to-date net income stands at $107 million compared to a net loss of $177 million in the prior year.
- 2Revenue growth driven by diversification: Net sales increased by 5% to $708 million in Q2 2002, with growth primarily coming from product lines excluding coronary stents and from acquired businesses.
- 3Strategic acquisitions bolster portfolio: Completed the acquisition of Enteric Medical Technologies (EMT) for GERD treatment and BEI Medical Systems for women's health, expanding the company's Endosurgery product offerings.
- 4Global operations optimization nearing completion: Substantially completed the plant optimization initiative, expected to yield significant cost savings and improve operational efficiency.
- 5Declining NIR stent sales continue: Acknowledged the ongoing decline in NIR(R) coronary stent sales, offset by growth in other product areas and the upcoming launch of the Express(TM) coronary stent.
- 6Increased R&D investment: Research and development expenses increased, particularly in drug-eluting stent technology like the TAXUS(TM) program, positioning for future product launches.
- 7Substantial debt and credit facilities: The company had $510 million in commercial paper outstanding and a $1.6 billion revolving credit facility available at quarter-end, indicating significant leverage but also access to funding.